Since 2008, downstream purification issues have become progressively more acute problems for biomanufacturers. But that’s begun to change this year, according to results from BioPlan Associates’ 9th ...

Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

Upstream titers of 3–5 g/L, and up to 10–13 g/L, are outpacing downstream capacity, creating chromatography, filtration, and UF/DF throughput bottlenecks that elevate cost and delay timelines. Complex ...

Downstream processing encompasses the sequence of operations required to isolate, purify and formulate a biopharmaceutical product from crude biological feedstock. Following cell culture or ...

In this brochure, Thermo Scientific takes a closer look at how integrated hot-melt extrusion (HME) workflows, paired with flexible downstream processing technologies from Thermo Fisher Scientific, can ...

Purifying novel therapeutics remains a major challenge as increasingly complex molecules move towards the clinic. With Lonza, you can ensure optimal product quality and bring your molecules to the ...